Palisade Bio Showcases Promising Preclinical Findings for PALI-2108
During the prestigious Digestive Disease Week (DDW) 2025, Palisade Bio, Inc. (NASDAQ: PALI) presented compelling preclinical data showcasing PALI-2108's potential as a colon-specific PDE4 inhibitor. The data reveals significant insights into the drug's ability to effectively modulate inflammatory pathways in the colon, fostering a favorable immune response among patients suffering from ulcerative colitis (UC) and other inflammatory bowel diseases.
Key Insights from Preclinical Data
The preclinical studies conducted on PALI-2108 demonstrated its efficacy and safety profile, particularly in mouse models of colitis. The data focused on the drug's effect on PDE4B expression, cAMP levels, and the suppression of TNF-?, vital factors in managing the symptoms of UC. Dr. Mitch Jones, the Chief Medical Officer of Palisade Bio, expressed enthusiasm about these developments, highlighting their commitment to advancing PALI-2108 through Phase 1a/b clinical trials.
Understanding the Mechanism of PALI-2108
PALI-2108 operates as a prodrug that becomes bioactivated specifically in the colon. This process importantly reduces colon tissue PDE4B levels in a dose-dependent manner, which has been shown to enhance cAMP levels while significantly suppressing TNF-? compared to standard treatments. This unique mechanism is central to its therapeutic promise for patients battling inflammatory bowel diseases.
Clinical Parameters and Efficacy
In an experiment aimed at inducing colitis in mice using 4% dextran sulfate sodium in drinking water, the treatment with PALI-2108 resulted in marked improvements in several clinical parameters. This includes enhanced body weight, length of the colon, and a favorable Disease Activity Index (DAI) score, showcasing its potential effectiveness in managing colitis symptoms.
Advancements in Clinical Trials
Palisade Bio is currently conducting a single-center, double-blind, placebo-controlled Phase 1a/b study to evaluate the safety and tolerability of PALI-2108 in healthy volunteers. In tandem, an open-label study is progressing involving patients diagnosed with ulcerative colitis. These trials aim to assess pharmacokinetics and pharmacodynamics thoroughly.
Palisade Bio: Pioneers in Therapeutics for Autoimmune Diseases
As a clinical-stage biopharmaceutical company, Palisade Bio reaffirms its dedication to transforming therapeutic approaches for patients experiencing autoimmune, inflammatory, and fibrotic diseases. The innovative strategy of leveraging targeted pharmacological therapies aims to redefine treatment standards and improve quality of life for those affected.
Future Outlook for PALI-2108
With the growing body of evidence from preclinical and clinical studies, Palisade Bio is optimistic about the future of PALI-2108 as a vital treatment option. The commitment to report topline data from their completed Phase 1a study by the end of May underscores their focus on transparency and progress.
Frequently Asked Questions
What are the primary findings of the PALI-2108 study?
The study indicated that PALI-2108 significantly improves clinical parameters of colitis, reduces PDE4B expression in colon tissues, and enhances cAMP levels.
What diseases could PALI-2108 potentially treat?
PALI-2108 is being developed primarily for the treatment of ulcerative colitis and other inflammatory bowel diseases.
How does PALI-2108 work in the body?
PALI-2108 acts as a prodrug that is bioactivated in the colon, leading to reduced inflammatory markers and improved patient outcomes.
What are the next steps for Palisade Bio?
The company is conducting ongoing clinical trials for PALI-2108 and aims to report topline data from the Phase 1a trial soon.
How can I find more information about PALI-2108?
Additional information regarding PALI-2108 and the clinical trials can be found on Palisade Bio's official website and clinical trial registries.
